I copied and pasted BlueJays post to Adam and three additional media relations contact. Hopefully Adam response to me either confirming or denying.
Agree, hes a joke!! He's got his tail between his leg, I'm surprised he's even making any comments on the board. Go away pitwig, go find some other stock to hype up and pretend to know.
Need to drive it higher and get this trader out of the way.
Prima advises that it has filed for patent protection over the use of IMP321 in conjunction with checkpoint inhibitor molecules, which the company believes gives IMP321 significant clinical and commercial advantages.
Prima's CEO, Mar Voigt, and CSO & CMO, Professor Frederic Triebel, will be attending the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago to discuss IMP321 with key opinion leaders in the immune-oncology field.
The release continues but I cant cut and paste it wont let me. All in all, good release.
agree, I tried to email him and then no response there either
yeah yeah yeah. Heard it all week long. I'll believe it when I see it. I don't see it happening in the near future, maybe in a year or two. Company still has a long ways to go before bringing product to market.
Pitwig you have zero credibility and because of your pumping, I'm stuck in this stock deeper than I was prior to your ranting of news and such. Stupid me for drinking the koolaid but really man, shut up!!!
Prima BioMed and Japanese partners NEC and Yamaguchi University are investigating the use of an adjuvant for a potential liver cancer vaccine.
AsianScientist (May 19, 2015) - Prima BioMed Ltd., an immunotherapeutics company headquarted in Australia, will collaborate with NEC Corporation and Yamaguchi University to develop their peptide vaccine IMP321. The preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate the use of antigen presenting cell activator IMP321 as an adjuvant, together with peptide antigens believed to be involved in hepatocellular cancer. “We are very pleased to be able to assist NEC with this preclinical study.The use of IMP321 as an adjuvant to a vaccine is different to the other combination approaches being used for our planned clinical trials. The opportunity to broaden the application of IMP321 for other uses is exciting,” said Mr. Marc Voigt, CEO of Prima. This follows an earlier announcement by Prima BioMed on prioritizing its highly prospective LAG-3 based immunotherapy products. The company stated that it would consolidate its clinical trial program of CVac and pursue opportunities to market its cancer vaccine manufacturing infrastructure.
Cancer vaccine maker seeks partner
The developer of a new ovarian cancer vaccine is seeking a business partner to launch its treatment to patients across the globe following successful clinical trials.
Shares in Prima BioMed have shot up after the biotech announced strong results from clinical trials of its ovarian cancer CVac treatment.
Prima BioMed's shares finished up by 1.2 cents, or 54.55 per cent, to 3.4 cents.
The company said final data from a five-year trial of CVac had shown a clear improvement in patients suffering ovarian cancer.
The results showed the treatment extended the survival rate of patients in remission for the second time.
The median survival rate for second remission patients is about 25 months.
Prima BioMed said the trial showed CVac gave patients at least another 16 months.
The company's chairman Lucy Turnbull said the final clinical data for CVac was most encouraging for cancer patients in second remission.
"Our concerted focus will now be to find a development partner to make CVac widely available to cancer sufferers around the world," Ms Turnbull said.
The vaccine stimulates patients' own immune system to target and destroy cancer cells.